BioSpace News Archive

Monogram Orthopaedics Inc. today provided an update related to the regulatory and commercialization path for its mBos surgical system following its meeting with the U.S. Food and Drug Administration.

Bionet America, Inc. announced the launch of the new Brio XVet series, a groundbreaking line of multiparameter monitors for use in veterinary surgery.

Marinus Pharmaceuticals, Inc. today announced that it plans to release financial results for the first quarter ended March 31, 2024 before market open on May 8, 2024.

Agilent Technologies Inc. (NYSE: A) has announced the NovoCyte Opteon Spectral Flow Cytometer, propelling flow cytometry into a new era of and accessibility.

Yield10 Bioscience, Inc., an agricultural bioscience company, announced that it will effect a 1-for-24 reverse stock split of its common stock, following stockholder approval of the reverse stock split at its special stockholder meeting held on April 26, 2024.

Veru Inc. today announced it will host a conference call and audio webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 second quarter financial results and to provide a business update.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”) today announces the preliminary data from Phase 2a trial of SLS009, a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia (r/r AML) and successful filing of a provisional patent application around the ASXL1 mutation and SLS009, including all CDK9 inhibitor drugs.

Aileron Therapeutics, Inc. today announced positive data from Cohort 1 of the ongoing Phase 1b clinical trial evaluating the safety and tolerability of inhaled LTI-03 in patients diagnosed with idiopathic pulmonary fibrosis (IPF).

Stealth BioTherapeutics Inc. today announced its participation at key upcoming ophthalmology conferences to discuss the Company’s clinical development efforts in dry age-related macular degeneration (dry AMD), including progression of lead investigational compound elamipretide into Phase 3 trials and development of pipeline compound bevemipretide (SBT-272) as a topical ophthalmic drop.

Altamira Therapeutics Ltd. today announced that it has filed a provisional patent application with the United States Patent Office (USPTO) which covers nanoparticles comprising the Company’s OligoPhore™ platform and siRNA targeting the p65 protein, a component of the NF-κB transcription factor.